Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study

BACKGROUND: To assess the risks of malignancies, infections and autoimmune diseases in patients with rheumatoid arthritis (RA) treated with abatacept compared with other biologic (b) disease-modifying antirheumatic drugs (DMARDs) or conventional synthetic (cs)DMARDs, in a US-wide observational RA co...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozen, Gulsen, Pedro, Sofia, Schumacher, Rebecca, Simon, Teresa A., Michaud, Kaleb
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555014/
https://www.ncbi.nlm.nih.gov/pubmed/31174592
http://dx.doi.org/10.1186/s13075-019-1921-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555014/
https://www.ncbi.nlm.nih.gov/pubmed/31174592
http://dx.doi.org/10.1186/s13075-019-1921-z

Ejemplares similares